ReviewExpert review of neurotherapeutics2014
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.
Review in Expert review of neurotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanisms Underlying the Efficacy of Prolonged Exposure
Mechanisms Underlying Efficacy of Prolonged Exposure
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Recent Progress in Virtual Reality Exposure Therapy for Phobias: A Systematic Review.Current psychiatry reports · 2017Pooled it
- A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.The Journal of clinical psychiatry · 2017Pooled it
- Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder.Current neuropharmacology · 2017Pooled it
- Bothersome tics in patients with chronic tic disorders: Characteristics and individualized treatment response to behavior therapy.Behaviour research and therapy · 2015Trial
- Optogenetic stimulation of the infralimbic cortex prior to fear extinction learning rescues deficits in a preclinical model of comorbid PTSD and AUD.Psychopharmacology · 2026Article
- An integrative model of perseverative thinking.Dialogues in clinical neuroscience · 2025Review
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Clinical Effects of Asynchronous Provider-Guided Practice Sessions During Blended Care Therapy for Anxiety and Depression: Pragmatic Retrospective Cohort Study.Journal of medical Internet research · 2024Article
- The Impact of Continuous and Partial Reinforcement on the Acquisition and Generalization of Human-Conditioned Fear.Behavioral sciences (Basel, Switzerland) · 2024Article
- Things that make you go Hmm: Myths and misconceptions within cognitive-behavioral treatment of obsessive-compulsive disorder.Journal of obsessive-compulsive and related disorders · 2023Article
- Impact of Stress and Exercise on Fear Extinction.Current topics in behavioral neurosciences · 2023Article
- Propranolol Administration Modulates Neural Activity in the Hippocampal Hilus During Fear Retrieval.Frontiers in behavioral neuroscience · 2022Article
- Optogenetic manipulation of the prelimbic cortex during fear memory reconsolidation alters fear extinction in a preclinical model of comorbid PTSD/AUD.Psychopharmacology · 2021Article
- Neuropeptide Y as Alternative Pharmacotherapy for Antidepressant-Resistant Social Fear.International journal of molecular sciences · 2020Article
- Development of the Response to Fearful Situations Scale.Behavioural and cognitive psychotherapy · 2020Article
- Associations between PTSD-Related extinction retention deficits in women and plasma steroids that modulate brain GABANeurobiology of stress · 2020Article
- Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Brain-derived neurotrophic factor Val66Met genotype modulates amygdala habituation.Psychiatry research. Neuroimaging · 2017Article
- Extinction learning in childhood anxiety disorders, obsessive compulsive disorder and post-traumatic stress disorder: implications for treatment.Expert review of neurotherapeutics · 2016Review
- The effect of D-cycloserine on social anxiety treatment using a behavioral outcome measure and a post-session administration strategy.Behavior analysis (Washington, D.C.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Translating findings from basic science, several compounds have been identified that may enhance therapeutic outcomes and/or expedite treatment gains when administered alongside exposure-based treatments. Four of these compounds (referred to as cognitive enhancers) have been evaluated in the context of randomized controlled trials for anxiety disorders (e.g., specific phobias, panic disorder, social anxiety disorder), obsessive-compulsive disorder and post-traumatic stress disorder. These cognitive enhancers include D-cycloserine, yohimbine hydrochloride, glucocorticoids and cortisol and brain-derived neurotrophic factor. There is consistent evidence that cognitive enhancers can enhance therapeutic outcomes and/or expedite treatment gains across anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Emerging evidence has highlighted the importance of within-session fear habituation and between-session fear learning, which can either enhance fear extinction or reconsolidate of fear responses. Although findings from these trials are promising, there are several considerations that warrant further evaluation prior to widespread use of cognitive enhancers in exposure-based treatments. Consistent trial design and large sample sizes are important in future studies of cognitive enhancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.